JP2018520657A5 - - Google Patents

Info

Publication number

JP2018520657A5

JP2018520657A5 JP2017561902A JP2017561902A JP2018520657A5 JP 2018520657 A5 JP2018520657 A5 JP 2018520657A5 JP 2017561902 A JP2017561902 A JP 2017561902A JP 2017561902 A JP2017561902 A JP 2017561902A JP 2018520657 A5 JP2018520657 A5 JP 2018520657A5

Authority

JP

Japan

Prior art keywords

seq

sequence

variable region

cdr

cdr2

Prior art date

2016-05-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 7
• 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 6
• 206010028980 Neoplasm Diseases 0.000 claims 6
• 201000011510 cancer Diseases 0.000 claims 6
• 102000050320 human TNFRSF4 Human genes 0.000 claims 6
• 238000004519 manufacturing process Methods 0.000 claims 5
• 229940045513 CTLA4 antagonist Drugs 0.000 claims 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
• 239000004472 Lysine Substances 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 239000013604 expression vector Substances 0.000 claims 2
• 229960005386 ipilimumab Drugs 0.000 claims 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
• 229960003301 nivolumab Drugs 0.000 claims 2
• 150000007523 nucleic acids Chemical class 0.000 claims 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 229940124597 therapeutic agent Drugs 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical group OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 claims 1
• 206010005003 Bladder cancer Diseases 0.000 claims 1
• 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 1
• 206010008342 Cervix carcinoma Diseases 0.000 claims 1
• 206010009944 Colon cancer Diseases 0.000 claims 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 230000005867 T cell response Effects 0.000 claims 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
• 125000003275 alpha amino acid group Chemical group 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 210000004899 c-terminal region Anatomy 0.000 claims 1
• 201000010881 cervical cancer Diseases 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 238000006317 isomerization reaction Methods 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 201000005112 urinary bladder cancer Diseases 0.000 claims 1